1 General Information


MorphoSys AG (“the Company” or “MorphoSys”) is a leader in the development of highly efficient technologies for generating therapeutic anti­bodies. The Company’s proprietary portfolio of compounds and the pipeline of compounds co-developed with partners from the pharmaceutical and biotechnology industry is one of the broadest in the industry. The Group was founded as a German limited liability company in July 1992. In June 1998, MorphoSys became a German stock corporation. In March 1999, the Company completed its initial public offering on Germany’s “Neuer Markt”: the previous segment of the Deutsche Börse designated for high-growth companies. On January 15, 2003, MorphoSys AG was admitted to the Prime Standard segment of the Frankfurt Stock Exchange.

arrow-topCreated with sketchtool.Top arrow-rightCreated with sketchtool.2. Summary of Significant Accounting Policies